ULCERATIVE COLITIS
Clinical trials for ULCERATIVE COLITIS explained in plain language.
Never miss a new study
Get alerted when new ULCERATIVE COLITIS trials appear
Sign up with your email to follow new studies for ULCERATIVE COLITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New gut bacteria treatment for ulcerative colitis shows promise in early trial
Disease control TerminatedThis study tested an experimental treatment called VE202 in 114 people with mild-to-moderate ulcerative colitis. The goal was to see if VE202 could reduce inflammation in the colon and improve symptoms compared to a placebo. The trial was stopped early, but the results help resea…
Matched conditions: ULCERATIVE COLITIS
Phase: PHASE2 • Sponsor: Vedanta Biosciences, Inc. • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
Bile acid trial for pouchitis fails to finish
Disease control TerminatedThis study tested whether a bile acid supplement called UDCA could reduce inflammation and improve quality of life in people with pouchitis, a complication after surgery for ulcerative colitis. Only 2 participants were enrolled before the study was terminated early. The goal was …
Matched conditions: ULCERATIVE COLITIS
Phase: PHASE2, PHASE3 • Sponsor: Stanford University • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
Ulcerative colitis pill trial ends early – what happened?
Disease control TerminatedThis study tested an experimental oral drug, PF-07054894, in 44 adults aged 18-75 with mild to severe ulcerative colitis. The goal was to see if it could safely reduce inflammation and improve symptoms. The trial was terminated early, so results are limited.
Matched conditions: ULCERATIVE COLITIS
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
Ulcerative colitis drug study halted early
Disease control TerminatedThis study tested the long-term safety of a drug called efavaleukin alfa in people with moderate to severe ulcerative colitis. It was designed for patients who completed a previous year-long study and might benefit from continued treatment. However, the study was terminated early…
Matched conditions: ULCERATIVE COLITIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
Ulcerative colitis drug study halted: new treatment vs. entyvio
Disease control TerminatedThis study tested whether a new drug called AVT16 works as well as the approved drug Entyvio for people with moderate to severe ulcerative colitis. The study planned to include 301 adults aged 18 to 80. However, the study was terminated early, so results may not be complete.
Matched conditions: ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Alvotech Swiss AG • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Stem cell shot for gut disease shows early promise
Disease control TerminatedThis study tested a stem cell product called Remestemcel-L in 7 adults with severe ulcerative colitis that did not respond to standard treatments. The goal was to see if injecting these cells into the colon could reduce inflammation and help patients avoid surgery. The trial was …
Matched conditions: ULCERATIVE COLITIS
Phase: PHASE1, PHASE2 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug shows promise for ulcerative colitis relief
Disease control TerminatedThis study tested a new drug called efavaleukin alfa for people with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. About 221 adults took part, receiving either the drug or a placebo for 12 weeks, with an option to continue treatment for up …
Matched conditions: ULCERATIVE COLITIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New hope for ulcerative colitis? drug trial shows promise
Disease control TerminatedThis study tested a drug called vixarelimab in 79 people with moderate to severe ulcerative colitis who did not get better with other treatments. The goal was to see if the drug could help control the disease and reduce symptoms like diarrhea and bleeding. The study was stopped e…
Matched conditions: ULCERATIVE COLITIS
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Real-World tofacitinib study in ulcerative colitis ends early
Disease control TerminatedThis study aimed to see how well the drug tofacitinib (Xeljanz) works for people with moderate to severe ulcerative colitis in everyday medical practice in Switzerland. Researchers planned to track symptoms, quality of life, and a gut inflammation marker over 8 weeks. The study w…
Matched conditions: ULCERATIVE COLITIS
Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
Statins as gut microbiome modulators for ulcerative colitis: a failed promise?
Disease control TerminatedThis study tested whether statins, a common cholesterol drug, could change gut bacteria to reduce inflammation in people with ulcerative colitis. It included 177 adults with mild to moderate disease. The study was terminated early, so results are limited, but the idea was to see …
Matched conditions: ULCERATIVE COLITIS
Phase: PHASE2, PHASE3 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated May 01, 2026 16:01 UTC